SynthesisBiomolecules & biomedicine2025
Effect of SGLT2 inhibitors on liver fat content: A meta-analysis.
Synthesis in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.European journal of clinical pharmacology · 2026Pooled it
- Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications.BMJ open gastroenterology · 2026Review
- Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.Hepatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major metabolic disorder linked to increased morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors, commonly used to manage type 2 diabetes (T2DM), have shown potential in reducing liver fat content (LFC). However, the magnitude and consistency of this effect remain uncertain. This meta-analysis aimed to evaluate the impact of SGLT2 inhibitors on LFC in adults with metabolic disorders. A systematic search of PubMed, Embase, the Cochrane Library, and Web of Science was conducted up to January 2, 2024, to identify randomized controlled trials (RCTs) assessing the effects of SGLT2 inhibitors on LFC. Studies were included if they reported liver fat changes measured by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) or proton magnetic resonance spectroscopy (¹H-MRS). We pooled standardized mean differences (SMDs) and 95% confidence intervals (CIs) using a random-effects model to account for variability across studies. Thirteen RCTs with 14 datasets (n = 791 participants) were included. SGLT2 inhibitors significantly reduced LFC compared to controls (SMD: -0.73, 95% CI: -0.97 to -0.50; P < 0.001), with moderate heterogeneity (I² = 62%). Subgroup and meta-regression analyses did not identify any study characteristics-such as study design, diabetic status, patient demographics, baseline LFC, type of SGLT2 inhibitor, or treatment duration-as significant contributors to heterogeneity (all P > 0.05). In conclusion, SGLT2 inhibitors are associated with a significant reduction in LFC in adults, supporting their potential role in managing MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.